Treatment

Therapeutic ultrasound for brain disorders

SONOPROBE

At CarThera, we have by-passed the problem of the skull bone by taking advantage of the necessary clinical step of tumor biopsy before any treatment. No clinician worldwide can envision beginning a chemotherapy or radiotherapy treatment without a previous histological diagnosis. We have designed and developed a probe that is able to emit high intensity ultrasound that can be inserted within the tumor as a biopsy needle under local anesthesia.  The probe performs not only the necessary biopsy but also the ultrasound treatment of the tumor in the same procedure under real-time MRI control.

 

SONOCLOUD

Ultrasound emitted at a lower intensity is also able to interact with the biological tissue without destroying it. Using low-intensity pulsed ultrasound, it is possible to temporarily make the blood vessels more porous to drugs. In the brain, the vessels are particularly tight (Blood-Brain Barrier or BBB), preventing the penetration of chemotherapy in the brain and significantly reducing its effectiveness.

At CarThera®, we have developed an implantable medical device containing a low intensity ultrasound transducer, the SonoCloud®, which is able to temporarily open the blood-brain barrier. At each chemotherapy session, the BBB can be opened in order to optimize the penetration of the chemotherapy in the brain while reducing the side effects in the rest of the body.

  • unnamed-2
    unnamed-3

     
  • News CarThera

    25.06.2019
    June 2019: CarThera appoints Pascal E. R. Girin as chairman of board of directors

    Pascal Girin brings wealth of experience in medical device and life sciences industries to support CarThera’s future growth. Girin has decades of business expertise in the life sciences and medical devices markets, most recently as CEO of Balt, a leader in the treatment of neurovascular diseases. Prior to this, he held numerous C-level positions at leading medical companies, including Wright Medical, Keystone Dental (a Warburg Pincus company), EV3, Baxter and Ohmeda, among others. As chairman of CarThera’s board of directors, he will bring invaluable insight to the company’s business strategy and future development.

    25.06.2019
    March 19: CarThera publishes complete results of Phase I/IIa clinical trial using its SonoCloud-1 ultrasound implant

    Final results of the phase I/IIa clinical trial (NCT02253212) on the ultrasound-induced blood-brain barrier (BBB) opening improving the efficiency of carboplatin chemotherapy for recurrent glioblastoma patients were published in AACR’s Clinical Cancer Research journal of the . Study results show a good safety profile and encouraging efficacy. These results are based on 65 sonication sessions with escalating ultrasound pressure levels. GBM patients treated with optimal pressure levels and MRI-detected disrupted BBB (11 patients) showed a median progression-free survival (PFS) of 4.11 months and a median overall survival (OS) of 12.94 months. This compares to 2.73 months and 8.64 months respectively, for GBM patients without BBB disruption (8 patients).

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.